KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim

FDA advisory committee unimpressed with 'baby step' to prevent snorting abuse, but the immediate release hydrocodone combo product seems headed to the market even without a differentiated label.